Reported 2 days ago
Truist analyst David MacDonald has lowered the price target for Elevance Health (NYSE:ELV) from $510 to $500, while still maintaining a Buy rating. The company reported strong Q1 2025 results with adjusted EPS of $11.97, reflecting over 10% year-over-year growth. Elevance Health continues to expand its value-based care model and has seen positive retention rates in its Medicare Advantage segment, despite facing some cost challenges in Medicaid. The health benefits company, formerly known as Anthem Inc., is well-regarded in the market.
Source: YAHOO